Tolebrutinib is a Brutons Tyrosine Kinase inhibitor and it failed to inhibit relapsing MS in trials compared to teriflunomide and now it has failed to inhibit progression in primary progressive MS in the PERSEUS trial…..so is there a future for tolebrutinib in non relapsing progressive MS?
It has been approved in the Middle East but I suspect NICE won’t be so nice. What will the FDA think in secondary progressive MS. It missed non clinical endpoints there. it makes you worried.
So on to the next candidate. Fenibrutinib kit however was better than teriflunomide in relapsing MS and inhibited progression. according to press releases. fenibrutinib is sort of unique as it is reversible inhibitors. In cancer to non reversible inhibitors stop working as an insensitive variant.
Source: multiple-sclerosis-research.org